4,407 results match your criteria Tardive Dyskinesia


The TAAR5 agonist α-NETA causes dyskinesia in mice.

Neurosci Lett 2019 Apr 12;704:208-211. Epub 2019 Apr 12.

Department of Higher Nervous Activity and Psychophysiology, Saint Petersburg State University, 7/9 Universitetskaya Emb., 199034, St Petersburg, Russia. Electronic address:

It is known that trace amine-associated receptor 5 (TAAR5) is expressed in various regions of the central nervous system. However, very limited information is available on the behavioral effects of TAAR5 activation and the TAAR5 functional role, in general. We studied the effect of TAAR5 agonist (2-(alpha-naphthoyl) ethyltrimethylammonium iodide) systemic administration on animal behavior. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043940193026
Publisher Site
http://dx.doi.org/10.1016/j.neulet.2019.04.028DOI Listing
April 2019
1 Read

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin.

Front Pharmacol 2019 20;10:281. Epub 2019 Mar 20.

Psychiatry Service, Health Care Complex, Salamanca, Spain.

We report on a patient with tardive dyskinesia (TDK) treated with aripiprazole, a third-generation antipsychotic with partial D2 agonist-antagonist activity at both the dopamine and serotonin receptors. The patient's condition improved with administration of a combination of tetrabenazine, botulinum toxin, and clozapine, which has previously not been used. We suggest that this treatment combination may have potential benefits for patients with TDK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435569PMC

Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia.

Chin J Physiol 2019 Jan-Feb;62(1):17-26

Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, ROC.

Having powerful antioxidative properties, L-theanine (LT), one of the major amino acid components in green tea, has potent anti-oxidative and neuroprotective effects. In this study, we examined the potential protective effects of LT on haloperidol (HAL)-induced orofacial dyskinesia (OD) in rats. HAL treatment (1 mg/kg intraperitoneally for 21 days) induced OD; significant increases (P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/CJP.CJP_8_19DOI Listing
April 2019
1 Read

Olanzapine Associated Acute Peripheral Edema and Pericardial Effusion: A Case Report.

Noro Psikiyatr Ars 2019 Mar 31;56(1):79-81. Epub 2019 Jan 31.

Department of Cardiology, Medipol University Faculty of Medicine, İstanbul, Turkey.

Olanzapine is a potent atypical antipsychotic drug used for the treatment of schizophrenia and bipolar disorder with approved efficiency. Olanzapine is superior to the typical antipsychotic drugs with low incidence of extrapyramidal side effects, especially tardive dyskinesia. The most common side effects associated with olanzapine are constipation, dyspepsia, weight gain, somnolence, asthenia, dry mouth and dizziness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29399/npa.22860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427082PMC
March 2019
1 Read

77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):214-215

8Executive Director,Medical Affairs,Neurocrine Biosciences,Inc.,San Diego,CA.

Background: Patients treated with antipsychotics, regardless of psychiatric diagnosis, are at risk for developing tardive dyskinesia (TD), a potentially debilitating drug-induced movement disorder. Valbenazine (INGREZZA; VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat TD in adults. Data from KINECT 4 (NCT02405091) were analyzed to evaluate the long-term effects of VBZ in adults with schizophrenia/schizoaffective disorder (SZD) or mood disorder (MD) and moderate or severe TD. Read More

View Article

Download full-text PDF

Source
https://www.cambridge.org/core/product/identifier/S109285291
Publisher Site
http://dx.doi.org/10.1017/S1092852919000579DOI Listing
February 2019
9 Reads

67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder.

CNS Spectr 2019 Feb;24(1):210-211

8Executive Director,Medical Affairs,Neurocrine Biosciences,Inc.,San Diego,CA.

Objective: Valbenazine is approved for tardive dyskinesia (TD) in adults based on clinical trials that included patients with mood disorders (e.g., bipolar disorder, major depressive disorder). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S109285291900052XDOI Listing
February 2019
5 Reads

62 Predictors of Tardive Dyskinesia in Psychiatric Patients Taking Concomitant Antipsychotics.

CNS Spectr 2019 Feb;24(1):207-208

2Teva Pharmaceuticals,Frazer,Pennsylvania,USA.

Background: Tardive dyskinesia (TD) is typically caused by exposure to antipsychotics, is often irreversible, and can be debilitating. TD symptoms can increase the social stigma of patients with comorbid psychiatric disorders, negatively impact quality of life, and potentially increase medical morbidity and mortality. An increased risk of developing TD has been associated with factors such as older age, female sex, underlying mental illness, and long-term use and higher doses of antipsychotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000488DOI Listing
February 2019
4 Reads

46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

CNS Spectr 2019 Feb;24(1):201

12Georgetown University,Washington,District of Columbia,USA.

Study ObjectiveTo evaluate the long-term safety and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD) at 2years.

Background: In the 12-week ARM-TD and AIM-TD studies, deutetrabenazine showed clinically significant improvements in Abnormal Involuntary Movement Scale scores compared with placebo, and there were low rates of overall adverse events (AEs) and discontinuations associated with deutetrabenazine.

Method: Patients who completed ARM-TD or AIM-TD were included in this open-label, single-arm extension study, in which all patients restarted/started deutetrabenazine 12mg/day, titrating up to a maximum total daily dose of 48mg/day based on dyskinesia control and tolerability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000397DOI Listing
February 2019
1 Read

45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study.

CNS Spectr 2019 Feb;24(1):200-201

12Georgetown University,Washington,District of Columbia,USA.

Study ObjectiveTo evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining response rates from baseline in Abnormal Involuntary Movement Scale (AIMS) scores. Preliminary results of the responder analysis are reported in this analysis.

Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels, and there were low rates of overall adverse events and discontinuations associated with deutetrabenazine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000385DOI Listing
February 2019

41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):197-198

7Professor of Psychiatry and Behavioral Sciences,Stanford University School of Medicine,Stanford,CA.

Objective: Vesicular monoamine transporter 2 (VMAT2) inhibitors are the first class of drugs approved to treat tardive dyskinesia (TD). With the recent approval of these medications, a modified Delphi process was implemented to address the need for updated clinical guidelines for TD screening, diagnosis, and treatment.

Methods: A Steering Committee of 11 TD experts met in a Nominal Group meeting format to discuss/prioritize questions to be addressed about TD and identify individuals to be invited to serve as Delphi survey panelists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000348DOI Listing
February 2019
2 Reads

39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):196

6Executive Director,Medical Affairs,Neurocrine Biosciences,Inc.,San Diego,CA.

Objective: To evaluate the long-term safety and tolerability of once-dailyvalbenazine in adults with tardive dyskinesia(TD).

Methods: Data were pooled from KINECT 3 (NCT02274558: 6-week double-blind placebo-controlled period, followed by a 42-week double-blind extension and 4-week drug-free washout) and KINECT 4 (NCT02405091: 48-week open-label treatment period and 4-week drug-free washout). KINECT 3/4 study completers could enroll in a subsequent rollover study (NCT02736955: up to 72weeks of open-label treatment or until valbenazine became commercial available); data from this study were described separately for this analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000324DOI Listing
February 2019
2 Reads

38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):195-196

8Executive Director,Medical Affairs,Neurocrine Biosciences,Inc.,San Diego,CA.

Objective: Valbenazine (VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat tardive dyskinesia (TD) in adults. It has been evaluated in 2 long-term studies (KINECT 3, KINECT 4) in which participants received VBZ (40 or 80mg) for up to 48weeks. This long-term rollover study (NCT02736955) was conducted to evaluate global TD improvement and patient satisfaction with once-daily VBZ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000312DOI Listing
February 2019
1 Read

35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):193-194

10Cleveland Clinic,Cleveland,Ohio,USA.

Background: Tardive dyskinesia (TD) is an often-irreversible movement disorder that may intensify the stigma of patients with psychiatric disorders and worsen quality of life. In two randomized, double-blind, placebo (PBO)-controlled, 12-week trials, ARM-TD and AIM-TD ('parent studies'), deutetrabenazine (DTB) demonstrated statistically significant improvements in centrally read Abnormal Involuntary Movement Scale (AIMS) scores at Week 12 compared with PBO and was generally well tolerated.Study ObjectiveTo evaluate the long-term efficacy of DTB in an open-label safety study following double-blind treatment using site-rated efficacy measures: AIMS, the Clinical Global Impression of Change (CGIC) and the Patient Global Impression of Change (PGIC), which may be used in real-world clinical practice settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000294DOI Listing
February 2019

34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities.

CNS Spectr 2019 Feb;24(1):193

10Cleveland Clinic,Cleveland,Ohio,USA.

Background: Tardive dyskinesia (TD) results from exposure to dopamine-receptor antagonists (DRAs), such as typical and atypical antipsychotics. Clinicians commonly manage TD by reducing the dose of or stopping the causative agent; however, this may cause psychiatric relapse and worsen quality of life. In the 12-week ARM-TD and AIM-TD trials, deutetrabenazine demonstrated statistically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores versus placebo and was generally well tolerated, regardless of baseline DRA use or comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000282DOI Listing
February 2019
3 Reads

6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECTStudy.

CNS Spectr 2019 Feb;24(1):176-177

9Senior Director,HEOR,Neurocrine Biosciences,Inc.,San Diego,CA.

Objective: Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with antipsychotic treatment. RE KINECT (NCT03062033), a real-world study of outpatients prescribed antipsychotics, was designed to identify the presence of possible TD and characterize the impact of involuntary movements on functioning and quality of life. Data from RE-KINECT were used to compare the impact of possible TD in patients with schizophrenia/schizoaffective disorder [SZD] versus mood/other psychiatric disorders [Mood]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S109285291900004XDOI Listing
February 2019
6 Reads

Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review.

Metab Brain Dis 2019 Mar 8. Epub 2019 Mar 8.

Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India.

Today, neurological disorders such as epilepsy, depression, tardive dyskinesia, and stress, and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, dementia, and Huntington's disease affect millions of people all over the world. Existing pharmacological interventions do not meet the desired therapeutic benefits for a significant number of patients, and hence, numerous research studies are in progress to find novel therapies for these disorders. Herbal drugs, which have been used in traditional medicine for centuries, are also being explored and scientifically evaluated for the treatment of these neurological disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11011-019-00400-9DOI Listing

The use of clozapine and clonazepam co-administration in the treatment of a severe tardive dyskinesia: A case report.

SAGE Open Med Case Rep 2019 25;7:2050313X19833254. Epub 2019 Feb 25.

Clinical Department, Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.

This is a case report of a patient who was treated with clozapine and clonazepam after he developed neuroleptic-induced tardive dyskinesia following treatment for schizophrenia. There are reports of clozapine treatment itself causing tardive dyskinesia; however, more reports have shown clozapine's benefit for patients with neuroleptic-induced tardive dyskinesia. This is a case report of a patient with neuroleptic-induced tardive dyskinesia who benefitted from clozapine treatment with adjuvant use of clonazepam - the first such case report from Ethiopia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X19833254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393946PMC
February 2019

Pineal gland and schizophrenia: A systematic review and meta-analysis.

Psychoneuroendocrinology 2019 Feb 25;104:100-114. Epub 2019 Feb 25.

Federal University of Juiz de Fora, School of Medicine, Av. Eugênio do Nascimento, s/n - Dom Bosco, Juiz de Fora, MG, 36036-330, Brazil.

Melatonin (MLT), the main hormone of the pineal gland (PG), is assumed to support initiation and maintenance of sleep, and a stable sleep-wake cycle, exerting antioxidative and neuroprotective actions. Evidence demonstrates that sleep and circadian rhythm abnormalities are very common in schizophrenia patients. Some imaging studies suggest structural abnormalities of the PG in these patients as well. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03064530183074
Publisher Site
http://dx.doi.org/10.1016/j.psyneuen.2019.02.024DOI Listing
February 2019
4 Reads

Treatment Recommendations for Tardive Dyskinesia.

Can J Psychiatry 2019 Feb 21:706743719828968. Epub 2019 Feb 21.

1 Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.

Background:: Tardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide recommendations on the treatment of tardive dyskinesia.

Methods:: We performed a systematic review of studies of the treatment of tardive dyskinesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0706743719828968DOI Listing
February 2019
2 Reads

Response to Letter to the Editor.

Tremor Other Hyperkinet Mov (N Y) 2019 6;9:630. Epub 2019 Feb 6.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, US.

In Response To: Walker RH. Reply to: Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/0rjw-cv10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377913PMC
March 2019
3 Reads

Reply to: Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Authors:
Ruth H Walker

Tremor Other Hyperkinet Mov (N Y) 2019 13;9:626. Epub 2019 Feb 13.

Department of Neurology, James J. Peters Veterans Affairs Medical Center, Bronx, New York, NY, US.

In Response To: D'Abreu A, Friedman JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/3rez-p096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377912PMC
March 2019
1 Read

Valbenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Feb 6. Epub 2019 Feb 6.

Rush University Medical Center, Section of Movement Disorders, Rush Parkinson's Disease & Movement Disorders Program, 1725 W Harrison St., Suite 755, Chicago, IL 60612, USA.

Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 2017, valbenazine became the first US FDA-approved medication indicated for the treatment of TD. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases the abnormal movements of TD. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nmt-2019-0001
Publisher Site
http://dx.doi.org/10.2217/nmt-2019-0001DOI Listing
February 2019
4 Reads

Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.

Curr Opin Psychiatry 2019 May;32(3):179-184

Department of Psychiatry, Psychotherapy, and Psychosomatics, Division of Psychiatry I, Medical University Innsbruck, Innsbruck, Austria.

Purpose Of Review: To provide an update on the frequency of antipsychotic-induced tardive dyskinesia and its management in patients with schizophrenia spectrum disorders in studies published since the last systematic review in 2008.

Recent Findings: Recent data about antipsychotic-induced tardive dyskinesia in patients with schizophrenia underscore the superiority of newer generation antipsychotics (21%) over first-generation antipsychotics (30%) with respect to prevalence and incidence rates. Regarding recently tested management strategies, the new vesicular monoamine transporter 2 inhibitors valbenazine and deutetrabenazine have been found to be effective and may be considered as first-line pharmacotherapy for tardive dyskinesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/YCO.0000000000000491DOI Listing
May 2019
1 Read

Deutetrabenazine in the treatment of tardive dyskinesia.

Neurodegener Dis Manag 2019 Jan 31. Epub 2019 Jan 31.

Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, 77030, USA.

Tardive dyskinesia is a common movement disorder in the population of patients taking dopamine receptor blocking agents, such as antipsychotics and certain antiemetics, which likely lead to D2-receptor upregulation and hypersensitization. Efficacious and well-tolerated treatments are now available to reduce symptoms. Deutetrabenazine, a reversible inhibitor of vesicular monoamine transporter 2, was US FDA-approved for treatment of tardive dyskinesia in 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nmt-2018-0042DOI Listing
January 2019
9 Reads

Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.

J Clin Psychiatry 2018 Dec 18;80(1). Epub 2018 Dec 18.

Neurocrine Biosciences, Inc, San Diego, California, USA.

Background: In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1-7). Data from this study were analyzed further to provide a more clinically meaningful interpretation of the primary AIMS results.

Methods: The study included adults who had a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or any mood disorder and also met DSM-IV criteria for neuroleptic-induced TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.18m12278DOI Listing
December 2018
5 Reads

Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.

J Clin Psychiatry 2019 Jan 8;80(1). Epub 2019 Jan 8.

FondaMental Foundation, Créteil, France.

Background: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing.

Objective: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
https://www.psychiatrist.com/JCP/article/Pages/2019/v80/18m1
Publisher Site
http://dx.doi.org/10.4088/JCP.18m12246DOI Listing
January 2019
23 Reads

Trigeminal Meningioma in a Patient with Tardive Dyskinesia as Only Symptom.

Case Rep Neurol Med 2018 31;2018:6175165. Epub 2018 Dec 31.

Clinical County Emergency Hospital of Sibiu, Department of Neurology, Romania.

Most meningiomas are benign, encapsulated tumors (95% of the cases), generally undergoing a limited number of genetic aberrations. We present the case of a 74-year-old patient with no significant pathological history, who is admitted to the neurology ward for orofacial dyskinesias accompanied by hypoesthesia in the left hemiface, a symptomatology that had started insidiously about two months before and worsened progressively over the past 3 weeks. A cerebral MRI was performed which revealed a small mass with discrete T2 hyperintensity and T1 iso-signal compared to the gray matter located in the left pontine cistern, with a large, well-defined base at the level of the cerebral tentorium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6175165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332992PMC
December 2018

Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates.

Mov Disord 2019 Jan 24. Epub 2019 Jan 24.

Faculté de Pharmacie, Université de Montréal, Montréal, Quebec, Canada.

Background: Tardive dyskinesia is a delayed and potentially irreversible motor complication arising from chronic exposure to antipsychotic drugs. Interaction of antipsychotic drugs with G protein-coupled receptors triggers multiple intracellular events. Nevertheless, signaling pathways that might be associated with chronic unwanted effects of antipsychotic drugs remain elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27630DOI Listing
January 2019

Antipsychotics for patients with pain.

Korean J Pain 2019 Jan 2;32(1):3-11. Epub 2019 Jan 2.

Department of Anesthesia and Pain Medicine, Pusan National University, Busan, Korea.

Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3344/kjp.2019.32.1.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333575PMC
January 2019
7 Reads

Potential Application of Yokukansan as a Remedy for Parkinson's Disease.

Evid Based Complement Alternat Med 2018 20;2018:1875928. Epub 2018 Dec 20.

College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, Gwangju 61186, Republic of Korea.

Parkinson's disease (PD), the second most common progressive neurodegenerative disorder, is characterized by complex motor and nonmotor symptoms. The clinical diagnosis of PD is defined by bradykinesia and other cardinal motor features, although several nonmotor symptoms are also related to disability, an impaired quality of life, and shortened life expectancy. Levodopa, which is used as a standard pharmacotherapy for PD, has limitations including a short half-life, fluctuations in efficacy, and dyskinesias with long-term use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1875928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317124PMC
December 2018
6 Reads

Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.

Prim Care Companion CNS Disord 2019 Jan 10;21(1). Epub 2019 Jan 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.18l02362DOI Listing
January 2019
1 Read

A Study on Drug-Induced Tardive Dyskinesia: Orofacial Musculature Involvement and Patient's Awareness.

J Orofac Sci 2018 Jul-Dec;10(2):86-95. Epub 2019 Jan 2.

Department of Oral and Maxillofacial Pathology, Ragas Dental College and Hospital, Affiliated to the Tamil Nadu Dr. M.G.R. Medical University.

Objective: Schizophrenia is a psychiatric disorder that requires long-term treatment. Long-term antipsychotic treatment is often associated with the emergence of tardive dyskinesia (TD), the severity of which is measured by Abnormal Involuntary Movement Scale (AIMS). This study examined the relationship among TD, orofacial musculature activity, and patient's awareness of AIM. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333421PMC
January 2019
8 Reads

The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.

Curr Med Res Opin 2019 Jan 13:1-10. Epub 2019 Jan 13.

b Teva Pharmaceutical Industries , Malvern , PA , USA.

Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications.

Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS ("TD + EPS" and "TD non-EPS") were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1569871DOI Listing
January 2019
2 Reads

Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors.

World J Biol Psychiatry 2019 Jan 9:1-6. Epub 2019 Jan 9.

f Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology & -Economics , University of Groningen , Groningen , the Netherlands.

Objectives: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia (TD). The authors tried to verify this hypothesis by testing for possible associations between two muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with schizophrenia.

Methods: A total of 472 patients with schizophrenia were recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15622975.2018.1548780DOI Listing
January 2019
5 Reads

No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia.

Hum Psychopharmacol 2019 Jan 8;34(1):e2685. Epub 2019 Jan 8.

Tomsk National Research Medical Center of the Russian Academy of Sciences, Mental Health Research Institute, Tomsk, Russia.

Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.2685DOI Listing
January 2019
3 Reads

Giant Tongue in a Patient With Chiari Malformation and Neuroleptic-Induced Tardive Dyskinesia.

J Craniofac Surg 2018 Dec 29. Epub 2018 Dec 29.

Department of Plastic, Reconstructive and Maxillo-Facial Surgery, and Burn Unit, Centro Hospitalar de São João, Porto Medical School, Alameda Professor Hernâni Monteiro, Porto, Portugal.

A 68-year-old woman, presented with a squamous cell carcinoma of the malar region, and underwent wide local excision. During her clinical examination, repetitive protrusion and intrusion of the tongue as well as stereotypic, abnormal movements of the mouth and lips were observed, in a pattern that resembled chewing, sucking or lip pursing; dyskinesias ceased when she was speaking or bringing food to the mouth. She was unaware of the movements and the tongue was observed to move similar to choreiform movements, while revealing a giant "snake-like" macroglossia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SCS.0000000000005066DOI Listing
December 2018

Current treatment of tardive dyskinesia.

Parkinsonism Relat Disord 2018 Dec 19. Epub 2018 Dec 19.

Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, S-3, Cleveland, OH, 44195, USA. Electronic address:

Tardive dyskinesia (TD) is a common, iatrogenic movement disorder affecting many individuals treated with dopamine-receptor blocking agents (DRBAs). Studying treatment of TD can be complex, as the symptoms can be affected by changes in either dosage or type of DRBA, as well as by the variable natural course of the disease. Historically many pharmacological therapies have been studied in TD, finding varying degrees of treatment success. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183055
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.12.022DOI Listing
December 2018
6 Reads

The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.

J Affect Disord 2019 03 17;246:217-223. Epub 2018 Dec 17.

Neurocrine Biosciences, Inc., San Diego, CA, United States.

Background: Few studies have assessed the treatment of tardive dyskinesia (TD) in patients with primary mood disorders who are managed with antipsychotics. The effects of once-daily valbenazine on TD were evaluated in adults with a bipolar or depressive disorder.

Methods: Data were pooled from two 6-week double-blind placebo-controlled trials (KINECT 2 and KINECT 3; 114 mood participants) and a long-term blinded extension study (KINECT 3 extension; 77 mood participants) of valbenazine in adults with TD. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01650327183128
Publisher Site
http://dx.doi.org/10.1016/j.jad.2018.12.023DOI Listing
March 2019
15 Reads

Risperidone-Induced Tardive Dyskinesia in an Autistic Child.

Authors:
Vasco Kidd

Prim Care Companion CNS Disord 2018 Dec 6;20(6). Epub 2018 Dec 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.18l02283DOI Listing
December 2018
2 Reads

Tardive dyskinesia: Who gets it and why.

Authors:
Karen Frei

Parkinsonism Relat Disord 2018 Nov 15. Epub 2018 Nov 15.

Loma Linda University, Loma Linda, CA, USA. Electronic address:

Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of antipsychotic agent, being greater for those of first generation antipsychotics (FGA), the duration of illness and cumulative dose of DRBA and advanced age. Female sex and African and Caucasian ethnicity are additional potential risk factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183051
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.017DOI Listing
November 2018
12 Reads

[Extrapyramidal adverse reactions to metoclopramide. A pharmacovigilance survey].

Rev Med Chil 2018 Jul;146(7):876-884

Servicio de Farmacia, Hospital La Ligua, La Ligua, Chile.

Background: In 2013 the Chilean regulatory sanitary agency issued a warning concerning dose adjustment and use restriction to avoid severe adverse effects of metoclopramide such tardive dyskinesia.

Aim: To study dyskinesia type adverse effects in a population using metoclopramide.

Material And Methods: A cross sectional observational study was conducted among patients pertaining to palliative care and diabetes mellitus programs and consuming 10 mg/day or more of metoclopramide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000700876DOI Listing
July 2018
1 Read

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183052
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.025DOI Listing
November 2018
3 Reads

Quantitative DNA Methylation Analysis of DLGAP2 Gene using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach.

Sci Rep 2018 Nov 30;8(1):17466. Epub 2018 Nov 30.

Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, China.

Tardive dyskinesia (TD) is a side effect of antipsychotic medications used to treat schizophrenia (SCZ) and other mental health disorders. No study has previously used pyrosequencing to quantify DNA methylation levels of the DLGAP2 gene; while the quantitative methylation levels among CpG sites within a gene may be correlated. To deal with the correlated measures among three CpG sites within the DLGAP2 gene, this study analyzed DNA methylation levels of the DLGAP2 gene using a linear mixed model (LMM) in a Chinese sample consisting of 35 SCZ patients with TD, 35 SCZ without TD (NTD) and 34 healthy controls (HCs) collected in Beijing, China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35718-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269460PMC
November 2018
3 Reads

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma.

Cureus 2018 Sep 24;10(9):e3349. Epub 2018 Sep 24.

Hematology and Oncology, University of Arizona, Tucson, USA.

Lenalidomide is commonly used as induction or maintenance therapy in multiple myeloma. We report a case of 71-year-old female presenting with tardive dyskinesia-like symptoms one month after starting her lenalidomide maintenance therapy after high-dose chemotherapy and autologous hematopoietic stem cell rescue. Her symptoms evolved over days to pronounced uncontrollable limb movements, tongue smacking, lip-smacking, abnormal sounds, and tongue biting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255714PMC
September 2018
2 Reads

Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.

Authors:
Sundar Gnanavel

Prim Care Companion CNS Disord 2018 Nov 22;20(6). Epub 2018 Nov 22.

View Article

Download full-text PDF

Source
http://www.psychiatrist.com/PCC/article/Pages/2018/v20n06/18
Publisher Site
http://dx.doi.org/10.4088/PCC.18l02275DOI Listing
November 2018
17 Reads

A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.

Agri 2018 Oct;30(4):199-201

Department of Anesthesiology and Reanimation, Zile State Hospital, Tokat, Turkey.

Tardive dyskinesia and tardive dystonia are caused by dopamine receptor blocking agents, mostly antipsychotics and sometimes antidepressants or calcium channel blockers. Duloxetine is a serotonin-noradrenaline reuptake inhibitor used in the treatment of diabetic neuropathic pain and fibromyalgia, as well as major depression. In this case, we aimed to discuss the tardive dyskinesia-like appearance of a patient using duloxetine due to fibromyalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5505/agri.2018.60134DOI Listing
October 2018
22 Reads

Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy.

Am J Geriatr Psychiatry 2019 Jan 14;27(1):84-90. Epub 2018 Sep 14.

Adult Neurodevelopment and Geriatric Psychiatry Division (PSA, TS, KP, BHM, TKR), Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry (PSA, TS, KP, BHM, TKR), University of Toronto, Toronto, Ontario, Canada.

Objective: Antipsychotic use in older patients is associated with many adverse effects, including tardive dyskinesia and extrapyramidal symptoms, which, in turn, increase the risk of falling. Antipsychotics are also associated with metabolic syndrome and cognitive impairment in older patients. Integrated care pathways (ICPs) are designed to manage specific conditions using standardized assessments and measurement-based interventions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10647481183048
Publisher Site
http://dx.doi.org/10.1016/j.jagp.2018.09.003DOI Listing
January 2019
36 Reads

Tardive Dyskinesia Should Not Be Overlooked.

J Child Adolesc Psychopharmacol 2019 Feb 2;29(1):72-74. Epub 2018 Nov 2.

1 Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/cap.2018.0084
Publisher Site
http://dx.doi.org/10.1089/cap.2018.0084DOI Listing
February 2019
13 Reads

Changes in recruitment of motor cortex excitation and inhibition in patients with drug-induced tardive syndromes.

Neurophysiol Clin 2019 Feb 23;49(1):33-40. Epub 2018 Oct 23.

Sobell Department of Motor Neuroscience and movement Disorders, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Objectives: It has recently been suggested that drug-induced tardive syndromes (TS) might be due to maladaptive plasticity, which increases motor excitability in cerebral cortex and basal ganglia. In order to test this hypothesis, we performed the first measurements of cortical excitability in TS.

Methods: Motor cortex excitability was examined using transcranial magnetic stimulation (TMS) in 22 TS patients and compared with that in 20 age and sex-matched healthy individuals. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09877053183021
Publisher Site
http://dx.doi.org/10.1016/j.neucli.2018.10.001DOI Listing
February 2019
17 Reads